Skip to main content
SIU Annual Conference Main banner
 
Presentation Icons
Surgery Day
Surgery Day
Bench-to-Bedside
Bench-to-Bedside
SIU@U
SIU@U
    Session Type: Symposium

    WUOF Symposium (Continued) - Session Five - Advanced Prostate Cancer

    Wednesday, October 29, 2025
    15:00 - 17:00 GMT+0

      Moderator(s)

    • Jan Philipp Radtke

      Deputy Head of the Department
      Department of Urology, University Hospital Duesseldorf, Germany

    • Vidit Sharma

      Assistant Professor of Urology
      Mayo Clinic, United States

    Scientific Committee: Rob Reiter, Caroline Moore, Peter Black, Shomik Sengupta, Peter Hammerer, Laurence Klotz

    Meeting Objectives:




    • Highlight Emerging Paradigms in Urologic Cancer Care:
      Explore how novel diagnostics, therapeutics, and care models are transforming management across prostate, bladder, and kidney cancers.


    • Promote Multidisciplinary Collaboration and Translational Research:
      Foster dialogue between urologists, oncologists, and radiation oncologists to accelerate bench-to-bedside innovation.

    Presentations:

    • 15:00 - 15:15 GMT+0
      How to Treat Oligometastatic Prostate Cancer: Is there a Role for Radical prostatectomy?

      Speaker: Derya Tilki – Martini-Klinik Prostate Cancer Center

    • 15:15 - 15:30 GMT+0
      Metastasis Directed Therapy: Wishful thinking?

      Speaker: Joe O’Sullivan – Queen's University Belfast

    • 15:30 GMT+0
      Debate: Best Treatment for mHSPC
    • 15:30 - 15:45 GMT+0
      Will PARP Inhibition in HRR Mutated Patients Become the New Standard?

      Speaker: Peter Hammerer – Academic Hospital Braunschweig

    • 15:45 - 16:00 GMT+0
      Doublet Therapy Should be the Treatment of Choice for Most High Risk mHSPC Patients

      Speaker: Bertrand Tombal

    • 16:00 - 16:15 GMT+0
      Triplet Therapy Should be Much More Widely Utilised for These Patients

      Speaker: Henry Woo – Blacktown Hospital

    • 16:15 - 16:20 GMT+0
      Discussion & Audience Voting
    • 16:20 GMT+0
      Debate: Best Treatment for mCRPC
    • 16:20 - 16:35 GMT+0
      PARP-Inhibition + ARPI for Unselected Patients or Only HRR Mutated Patients?

      Speaker: Stefanie Zschäbitz – University Hospital Heidelberg, Germany

    • 16:35 - 16:50 GMT+0
      PSMA-Targeted Radioligand Therapy in Taxan-Naive mCRPC Patients?

      Speaker: Robert Reiter – University of California Los Angeles

    • 16:50 - 17:00 GMT+0
      Concluding Remarks

      Speaker: Peter Hammerer – Academic Hospital Braunschweig